one other point, that is that india recently issued a compulsory license for a cancer drug called nexivar. the drug was priced at $69,000 per year for cancer patients for kidney and liver cancer in india, a company that recently had a per capita income of $13 per year. the government said $69,000 a year in india was not roently affordable. now, consequently, the secretary of commerce in the united states gathered a few weeks ago and met to complain about this. and ryan kirk listed this issue on the recent may 1st, august 31st special 301 report. so, yeah, it's a huge problem. and i think the one way i'd sort of think about this is in the united states, we're increasing the ipr protection. nobody thinks it's enough to do anything about. it's like we're a frog being put in a pot of water where it's being turned up one degree at a time. and we're just going to be cooked. it's worse than it was five years ago, it's worse than it was ten years ago. where is it going to be 20 years from now? this bill is to build a bridge for the future so the future is something that's consistent with human ri